الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 159 |  |  |
| | | from | 159 | | |
Abstract
The aim of this study is to assess the role of GDF 15 gene pleomorphism, it’s serum level and adropine level as a novel biomarker in evaluation, risk stratification of CVD, and find out if they have theraputic value or perfusion value in CVD for better diagnosis and prognosis of CVD. The study involved 55 patients admmited to specialized medicine hospital of mansoura university. Thirty-five patients with acute coronary syndrome (ACS), twenty patients were patients with AMI and fifteen patients have unstable angina pectoris and 20 healthy patients of the same age and sex as control group. Blood samples were taken to do the following tests; The patient’s blood picture, which includes hemoglobin level, white blood cell count, and platelet count, Blood lipids include TGs, HDL, LDL, and cholesterol, Liver functions, which include albumin, liver enzyme AST, ALT, bilirubin, and kidney functions, which include measuring the level of creatine in the blood.ELISA was used to evaluate the rate of adobe and the differential growth factor 15 in the blood.Also, DNA extraction and chain polymerase reaction were done to know the genetic polymorphism of the DGF- 15. It is possible to use the measurement of DGF-15 and the adropin level as indications in the early diagnosis of myocardial infarction and also patients with unstable angina. The most common genotype is CC followed by CG followed by GG in the area of Dakahlia and there is no difference in the genetic diversity of the DGF- 15 between UAP patients and AMI and normal people.